In view of the finding that the BRD4/IRS2 inhibitor cocktail downregulates the expression of PD‐L1 in melanoma cells, we propose that these inhibitors may represent an additional approach to reduce the expression of PD‐L1 in cancer cells. This evidence concerns the gene IRS2 and melanoma.